Dynavax Technologies Corporation $DVAX Shares Purchased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC increased its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 4.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 133,601 shares of the biopharmaceutical company’s stock after purchasing an additional 5,523 shares during the period. Exchange Traded Concepts LLC owned 0.11% of Dynavax Technologies worth $1,325,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. purchased a new stake in Dynavax Technologies in the first quarter valued at $312,000. GAMMA Investing LLC lifted its position in Dynavax Technologies by 88.4% in the first quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 3,627 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Dynavax Technologies in the first quarter valued at $2,477,000. Woodline Partners LP lifted its position in Dynavax Technologies by 48.4% in the first quarter. Woodline Partners LP now owns 1,178,763 shares of the biopharmaceutical company’s stock valued at $15,289,000 after acquiring an additional 384,288 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its position in Dynavax Technologies by 31.1% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 13,466 shares of the biopharmaceutical company’s stock valued at $175,000 after acquiring an additional 3,197 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. JMP Securities reissued a “market outperform” rating and issued a $32.00 price target on shares of Dynavax Technologies in a research report on Friday, August 22nd. Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Dynavax Technologies has a consensus rating of “Moderate Buy” and an average price target of $24.33.

Insider Buying and Selling at Dynavax Technologies

In related news, Director Scott Dunseth Myers purchased 3,800 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were bought at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the acquisition, the director directly owned 35,004 shares in the company, valued at $378,743.28. This trade represents a 12.18% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. 2.98% of the stock is currently owned by company insiders.

Dynavax Technologies Price Performance

DVAX stock opened at $9.69 on Tuesday. The stock has a market capitalization of $1.14 billion, a P/E ratio of -21.07 and a beta of 1.24. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. Dynavax Technologies Corporation has a one year low of $9.20 and a one year high of $14.63. The company has a 50 day moving average price of $10.46 and a two-hundred day moving average price of $10.88.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.12 by $0.02. The firm had revenue of $95.44 million during the quarter, compared to analysts’ expectations of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. As a group, sell-side analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.